David Gurwitz
Infectious Diseases · 2002–2020
A researcher in the Science corpus: 2 papers; trusts 2 researchers and is trusted by 2 researchers here, as inferred from the citation graph.
Subfields
- Infectious Diseases — 11 citations into it; #147 of 589 by trust here, #457 by citations
Whom David Gurwitz trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts David Gurwitz overall
Papers from David Gurwitz's perspective
Ordered by how strongly the researchers David Gurwitz trusts endorse each paper. Same corpus, a different order for every researcher.
- Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor (Nature)
- What’s new in the renin-angiotensin system?
- Angiotensin-converting enzyme 2 protects from severe acute lung failure (Nature)
- A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury (Nature Medicine)
- SARS and MERS: recent insights into emerging coronaviruses (Nature Reviews Microbiology)
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding (The Lancet)
- Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas (Proceedings of the National Academy of Sciences of the United States of America)
- Potential interventions for novel coronavirus in China: A systematic review (Journal of Medical Virology)
- Coronavirus covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate (British medical journal)
- Structure analysis of the receptor binding of 2019-nCoV (Biochemical and Biophysical Research Communications - BBRC)
Their papers
- A Human Genome Diversity Cell Line Panel (2002) — 1,033 citations
- Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics (2020) — 717 citations